Berge V - Search Results

1

PBX3 is a putative biomarker of aggressive prostate cancer.

Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA. Ramberg H, et al. Among authors: berge v. Int J Cancer. 2016 Oct 15;139(8):1810-20. doi: 10.1002/ijc.30220. Epub 2016 Jun 25. Int J Cancer. 2016. PMID: 27273830 Free article.

2

Complications of invasive, urodynamic examinations and prostate biopsies in patients with benign prostatic hyperplasia.

Berge V, Eri LM, Tveter KJ. Berge V, et al. Scand J Urol Nephrol Suppl. 1995;172:95-8. Scand J Urol Nephrol Suppl. 1995. PMID: 8578262

3

Test-retest variation of pressure flow parameters in men with bladder outlet obstruction.

Eri LM, Wessel N, Berge V. Eri LM, et al. Among authors: berge v. J Urol. 2001 Apr;165(4):1188-92. J Urol. 2001. PMID: 11257668

4

Comparative study of pressure-flow parameters.

Eri LM, Wessel N, Tysland O, Berge V. Eri LM, et al. Among authors: berge v. Neurourol Urodyn. 2002;21(3):186-93. doi: 10.1002/nau.10018. Neurourol Urodyn. 2002. PMID: 11948710

5

[Markers for diagnosis, prediction and prognosis of prostate cancer].

Taskén KA, Angelsen A, Svindland A, Eide T, Berge V, Wahlquist R, Karlsen S. Taskén KA, et al. Among authors: berge v. Tidsskr Nor Laegeforen. 2005 Dec 1;125(23):3279-82. Tidsskr Nor Laegeforen. 2005. PMID: 16327854 Free article. Norwegian.

6

Regulation of PBX3 expression by androgen and Let-7d in prostate cancer.

Ramberg H, Alshbib A, Berge V, Svindland A, Taskén KA. Ramberg H, et al. Among authors: berge v. Mol Cancer. 2011 May 6;10:50. doi: 10.1186/1476-4598-10-50. Mol Cancer. 2011. PMID: 21548940 Free PMC article.

7

Five-year progression-free survival in 577 patients operated on with laparoscopic radical prostatectomy for localized prostate cancer.

Berge V, Berg RE, Hoff JR, Wessel N, Svindland A, Karlsen SJ, Eri LM. Berge V, et al. Scand J Urol Nephrol. 2012 Feb;46(1):8-13. doi: 10.3109/00365599.2011.604790. Epub 2011 Aug 15. Scand J Urol Nephrol. 2012. PMID: 21843041

8

A prospective study of transition from laparoscopic to robot-assisted radical prostatectomy: quality of life outcomes after 36-month follow-up.

Berge V, Berg RE, Hoff JR, Wessel N, Diep LM, Karlsen SJ, Eri LM. Berge V, et al. Urology. 2013 Apr;81(4):781-6. doi: 10.1016/j.urology.2013.01.017. Epub 2013 Mar 7. Urology. 2013. PMID: 23465150

9

O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.

Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, Svindland A, Schlomm T, Mills IG. Itkonen HM, et al. Among authors: berge v. Cancer Res. 2013 Aug 15;73(16):5277-87. doi: 10.1158/0008-5472.CAN-13-0549. Epub 2013 May 29. Cancer Res. 2013. PMID: 23720054

10

Detection of the index tumour and tumour volume in prostate cancer using T2-weighted and diffusion-weighted magnetic resonance imaging (MRI) alone.

Rud E, Klotz D, Rennesund K, Baco E, Berge V, Lien D, Svindland A, Lundeby E, Berg RE, Eri LM, Eggesbø HB. Rud E, et al. Among authors: berge v. BJU Int. 2014 Dec;114(6b):E32-E42. doi: 10.1111/bju.12637. BJU Int. 2014. PMID: 24447606 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

90 results

Search Page